Latest Articles
Does Chemoradiotherapy Boost Survival in Endometrial Cancer? - Medscape
Does Chemoradiotherapy Boost Survival in Endometrial Cancer? Medscape
Published: Jan. 21, 2025, 9:45 a.m.
EC approves GSK’s Jemperli-chemo combo for endometrial cancer - Pharmaceutical Technology
EC approves GSK’s Jemperli-chemo combo for endometrial cancer Pharmaceutical Technology
Published: Jan. 21, 2025, 9:35 a.m.
GSK gets European Commission nod for expanded use of Jemperli in endometrial cancer - Medical Dialogues
GSK gets European Commission nod for expanded use of Jemperli in endometrial cancer Medical Dialogues
Published: Jan. 21, 2025, 8 a.m.
European Commission expands Jemperli plus chemotherapy approval for endometrial cancer - Indian Pharma Post
European Commission expands Jemperli plus chemotherapy approval for endometrial cancer Indian Pharma Post
Published: Jan. 21, 2025, 4:36 a.m.
Endometriosis and risk of cardiovascular disease: a systematic review and meta-analysis - BMC Public Health
Endometriosis and risk of cardiovascular disease: a systematic review and meta-analysis BMC Public Health
Published: Jan. 21, 2025, 1:41 a.m.
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR - ABN Newswire
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR ABN Newswire
Published: Jan. 21, 2025, 12:38 a.m.
Management of Diaphragmatic Central Tendon Plays an Important Role in the Surgical Treatment of Catamenial Pneumothorax: A Case Report - Cureus
Management of Diaphragmatic Central Tendon Plays an Important Role in the Surgical Treatment of Catamenial Pneumothorax: A Case Report Cureus
Published: Jan. 20, 2025, 9:41 p.m.
Dr Vetter on the Role of Trial Inclusion Criteria on Coverage for Pembrolizumab- and Dostarlimab-Based Regimens in Endometrial Cancer - OncLive
Dr Vetter on the Role of Trial Inclusion Criteria on Coverage for Pembrolizumab- and Dostarlimab-Based Regimens in Endometrial Cancer OncLive
Published: Jan. 20, 2025, 9:34 p.m.
GSK’s Jemperli combination approved by EC for expanded endometrial cancer use - PMLiVE
GSK’s Jemperli combination approved by EC for expanded endometrial cancer use PMLiVE
Published: Jan. 20, 2025, 12:33 p.m.
Gesynta Pharma Raises $29M to Advance Non-Hormonal Endometriosis Treatment - Femtech Insider
Gesynta Pharma Raises $29M to Advance Non-Hormonal Endometriosis Treatment Femtech Insider
Published: Jan. 20, 2025, 10:56 a.m.
Link copied to clipboard!